摘要
目的观察重组人血管内皮抑制素(恩度)联合热疗治疗恶性胸腹腔积液的近期疗效,评价恩度局部应用的安全性和耐受性。方法对45例伴有恶性胸腹腔积液的恶性肿瘤患者,随机分为恩度单药组23例、恩度联合化疗组22例,两组均联合局部射频热疗。恩度单药组注入恩度;联合化疗组同时接受顺铂胸腹腔局部灌注治疗。评价近期疗效、生活质量以及毒副反应。结果 45例患者均可进行客观疗效评价及安全性评价,恩度单药组CR 3例,PR 11例,SD 5例,PD 4例,客观有效率(RR)为60.9%,疾病控制率(DCR)为82.6%。联合组客观有效率高于单药组,但无统计学差异。药物相关性毒副反应不明显。结论恩度胸腹腔灌注给药联合热疗能较好地控制恶性胸腹水,减轻临床症状。恩度与化疗药物联合局部热疗可能具有一定的协同作用,安全性较好,化疗药物的不良反应无明显增加。
Objective To observe recombinant human endostatin（endostar） combined with hyperthermia treatment of malignant pleural effusion and ascites short-term effect,the evaluation of local application endostar the safety and tolerability.Methods Forty-five patients with malignant pleural effusion and ascites associated with malignant tumor were randomly divided into endostar monotherapy group with 23 cases,and endostar combined group with 22 cases.Two groups were combined with local hyperthermia.Single drug was injected endostar,chemotherapy group also received local infusion of cisplatin treatment of thoracic and abdominal cavity.Recent evaluation of efficacy,quality of life and toxicity were tested.Results Forty-five patients available for objective evaluation of efficacy and safety evaluation of single-agent group endostar CR 3 cases,PR 11 cases,SD 5 cases,PD 4 cases,objective response rate（RR） was 60.9%,disease control rate（DCR） was 82.6%.The objective response rate in combination group was higher than that of the single drug group,but there was no statistical difference.Drug-related toxicity was not obvious.Conclusion Endostatin combined with hyperthermia treatment can better control the thoracic and abdominal cavity perfusion to reduce the clinical symptoms.Endostar local hyperthermia combined with chemotherapy may have some synergistic effect,and side effects of chemotherapy do not increase.
出处
《实用临床医药杂志》
CAS
2011年第13期26-28,共3页
Journal of Clinical Medicine in Practice
关键词
重组人血管内皮抑制素
恶性胸腹腔积液
热疗
安全性
recombinant human endostatin
malignant pleural effusion and ascites
hyperthermia
security
